Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Group-based Metacognitive Therapy for PTSD in routine psychiatric care.

Official title: A Feasibility Study of Group-Based Metacognitive Therapy (MCT) for Post-Traumatic Stress Disorder (PTSD) in a Routine Healthcare Setting

Run by Karolinska Institutet · NCT07302334 · Data updated 2026-11-12

This project will try group-based Metacognitive Therapy (MCT) for adults with PTSD to see if people accept the treatment and whether symptoms and quality of life improve when it is offered in routine psychiatric care in Sweden.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment30 (estimated)
SponsorKarolinska Institutet
Academic / other
Locations1 site (Stockholm)
StatusRecruiting
StartedNovember 28, 2025
Main results expectedAugust 28, 2026
Study endsNovember 28, 2026
Registry record updatedDecember 24, 2025
Trial IDNCT07302334 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18) with a clinical diagnosis of PTSD, a self-rated PCL-5 total score over 30, stable psychotropic medication for at least 4 weeks, fluent in Swedish, and not currently receiving evidence-based trauma-focused therapy are ideal candidates.

Probably not a fit

Patients with severe psychiatric comorbidities requiring immediate attention (such as active suicidal ideation, psychosis, or bipolar disorder), those facing an ongoing trauma-related threat, or those already in trauma-focused therapy are unlikely to benefit from or be eligible for this program.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants will attend 14 weekly group MCT sessions delivered at a specialized psychiatric clinic in Stockholm with broadly inclusive recruitment and minimal exclusion criteria. Primary outcomes focus on feasibility and acceptability, including recruitment and retention rates, data completeness, treatment adherence, and qualitative feedback from participants. Secondary outcomes will measure preliminary changes in PTSD, complex PTSD, depressive symptoms, and quality of life, and will compare dropout rates to those reported for exposure-based PTSD treatments. Outcomes will be measured from pre-treatment to post-treatment and at a 6-month follow-up.

Why it matters

Potential benefit: If successful, group MCT could provide an acceptable, more scalable treatment option that reduces PTSD and depressive symptoms and improves functioning and quality of life for patients in routine care.

How similar studies have gone: Metacognitive Therapy has shown promising results for anxiety, depression, and some individual PTSD studies, but group-based MCT for PTSD delivered within routine psychiatric settings is relatively novel with limited prior data.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Fulfills the diagnostic criteria for PTSD based on clinical records
* Self-rated total sum score over 30 on the PCL-5
* Age ≥18 years.
* Stable psychotropic medication regimen for ≥4 weeks.
* Fluent in Swedish.

Exclusion Criteria:

* Severe psychiatric comorbidities (e.g., suicidal ideation, active psychosis, bipolar disorder) warranting immediate attention.
* Current trauma-related threat (e.g., ongoing domestic violence).
* Ongoing evidence-based trauma-focused psychological treatment

Where it's running

  • Affektiva, ångest och traumaprogrammet, Psykiatri Sydväst
    Stockholm, Sweden
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.